Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: May baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter-2 years-prospective study

Characteristics NTZ-JCV positive (n = 83) NTZ-JCV negative (n = 101) P-value
Age at disease onset (years), mean (SD) 29 (10) 26.5 (8.4) 0.07
Age at stratify (years), mean (SD) 39.6 (10.4) 38 (10.5) 0.29
Female (%) 53 (63.9) 74 (73.3) 0.20
Disease duration (years), mean (SD) 11.3 (8.1) 11.4 (8.6) 0.94
EDSS pre-stratify, median [IQR]; mean (SD) 3.5 (2–5); 3.1 (1.9) 3 (2–4); 3 (1.6) 0.017
Relapses year before stratify, median [IQR]; mean (SD) 1 (1–2); 1.34 (0.86) 1nn; 1.39 (0.80) 0.62
T2 lesions pre–stratify, mean (SD; IQR) 51.2 (38.5; 21–65) 51.6 (37.4; 20–70) 0.82
  1. IQR interquartile range, SD standard deviation
  2. NTZ Natalizumab, JCV John Cunningham virus